The pharma giant had previously labeled the drug trials a ‘lottery ticket,’ in a nod to the highly uncertain outcome. Novo Nordisk’s closely-watched Alzheimer’s trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on Monday, a blow to the obesity drug giant that sent its shares sliding.